Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment.

Giacomo CaldarolaLorenzo Maria PintoFrancesco BellinatoNicoletta BernardiniElena CampioneAndrea ChiricozziLaura ColonnaClara De SimoneLaura DiluvioPaolo GisondiEnrico MatteiniEleonora TomassettiErsilia TolinoLuca BianchiKetty Peris

Published in: Expert opinion on drug safety (2024)

It can be stated that, during treatment with JAKi in AA patients, infectious events may occur, but in most cases these events are easily manageable and do not result in permanent discontinuation of the drug.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
patient reported outcomes
risk factors
combination therapy
drug induced